Luspatercept for the Treatment of β-Thalassemia: from Preclinical Research to Clinical Practice and Beyond
Open Access
- 10 November 2021
- journal article
- review article
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 1 (4)
Abstract
β-thalassemia is an inherited disease causing an impaired hemoglobin production, eventually leading to a severe chronic anemia. Resolutive treatments are still limited to a small number of patients... Lay abstract β-thalassemia is an inherited disease causing a severe reduction of hemoglobin, the protein of red blood cells (RBCs) responsible of delivering oxygen to the body. This means a severe ...Keywords
This publication has 45 references indexed in Scilit:
- Non-transfusion-dependent thalassemiasHaematologica, 2013
- Beta-thalassemia: from genotype to phenotypeHaematologica, 2011
- Iron-Chelating Therapy for Transfusional Iron OverloadNew England Journal of Medicine, 2011
- The inherited diseases of hemoglobin are an emerging global health burdenBlood, 2010
- A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeysBone, 2010
- Global epidemiology of haemoglobin disorders and derived service indicatorsBulletin of the World Health Organization, 2008
- TGFβ–SMAD signal transduction: molecular specificity and functional flexibilityNature Reviews Molecular Cell Biology, 2007
- Hematopoietic Stem-Cell TransplantationNew England Journal of Medicine, 2006
- Global regulation of erythroid gene expression by transcription factor GATA-1Blood, 2004
- The Role of Activin A in Regulation of HemopoiesisStem Cells, 2002